BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 11:57:00 AM | Browse: 389 | Download: 433
Publication Name World Journal of Ophthalmology
Manuscript ID 15609
Country/Territory United Kingdom
Received
2014-12-01 09:45
Peer-Review Started
2014-12-01 19:48
To Make the First Decision
2015-01-20 13:35
Return for Revision
2015-01-22 15:15
Revised
2015-02-10 08:31
Second Decision
2015-03-24 16:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2015-04-07 16:17
Articles in Press
2015-04-07 16:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-04-27 16:04
Publish the Manuscript Online
2015-05-19 17:29
ISSN 2218-6239 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Ophthalmology
Manuscript Type Review
Article Title New treatments for diabetic macular edema
Manuscript Source Invited Manuscript
All Author List Farhan Husain Zaidi and Ejaz Ansari
Funding Agency and Grant Number
Corresponding author Farhan Husain Zaidi, PhD, FRCSs, FRCOphth, Department of Ophthalmology, Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Southwick Hill Road, Portsmouth, Hampshire PO6 3LY, United Kingdom. fhz12@hotmail.com
Keywords Diabetic macular edema; Diabetic macular oedema; Triamcinolone; Anti-vascular endothelial growth factor agents; Steroids; Non-steroidal anti-inflammatory drugs; Biologicals; Protein kinase C inhibitors
Core Tip Current evidence suggests the anti-vascular endothelial growth factor (anti-VEGF) agents aflibercept and ranibizumab are the most effective agents for most patients with diabetic macular edema. Aflibercept may be more effective when vision is very low. Other drugs retain niche roles including bevacizumab owing to lower costs, steroids like triamcinolone which can be effective many years later, dexamethasone and non-steroidal anti-inflammatory drugs like nepafenac. Also considered are anti-tumour necrosis factor agents like infliximab, anti-interleukins like canakinumab, anti-inflammatories including minocycline, rapamycin (sirolimus) and protein kinase C inhibitors midostaurin and ruboxistaurin. Fluocinolone implants, anti-VEGF agents bevasiranib and pegaptinib, cyclo-oxygenase-2 inhibitors like celecoxib, phospholipase A2 inhibitors and recombinant erythropoietin are discussed.
Publish Date 2015-05-19 17:29
Citation Zaidi FH, Ansari E. New treatments for diabetic macular edema. World J Ophthalmol 2015; 5(2): 45-54
Url http://www.wjgnet.com/2218-6239/full/v5/i2/45.htm
DOI http://dx.doi.org/10.5318/wjo.v5.i2.45
Full Article (PDF) WJO-5-45.pdf
Full Article (Word) WJO-5-45.doc
Manuscript File 15609-Review.doc
Answering Reviewers 15609-Answering reviewers.pdf
Audio Core Tip 15609-Audio core tip.wav
Conflict-of-Interest Disclosure Form 15609-Conflict-of-interest statement.pdf
Copyright License Agreement 15609-Copyright assignment.pdf
Peer-review Report 15609-Peer-review(s).pdf
Scientific Misconduct Check 15609-Scientific misconduct check.pdf
Scientific Editor Work List 15609-Scientific editor work list.pdf